DK2768851T3 - Antigener afledt af citrullineret 14-3-3 og anvendelser deraf i diagnosen af rheumatoid arthritis - Google Patents

Antigener afledt af citrullineret 14-3-3 og anvendelser deraf i diagnosen af rheumatoid arthritis Download PDF

Info

Publication number
DK2768851T3
DK2768851T3 DK12842377.9T DK12842377T DK2768851T3 DK 2768851 T3 DK2768851 T3 DK 2768851T3 DK 12842377 T DK12842377 T DK 12842377T DK 2768851 T3 DK2768851 T3 DK 2768851T3
Authority
DK
Denmark
Prior art keywords
citrullinated
protein
glu
fragment
eta
Prior art date
Application number
DK12842377.9T
Other languages
English (en)
Inventor
Anthony Marotta
Original Assignee
Augurex Life Sciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Augurex Life Sciences Corp filed Critical Augurex Life Sciences Corp
Application granted granted Critical
Publication of DK2768851T3 publication Critical patent/DK2768851T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/18—Post-translational modifications [PTMs] in chemical analysis of biological material citrullination
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/105—Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (18)

1. Isoleret citrullineret 14-3-3-eta-protein eller fragment deraf, der specifikt genkendes af anti-14-3-3-eta-autoantistoffer til stede i serummet fra en patient, der lider af en artritisk tilstand; hvor 14-3-3-eta-proteinet eller fragmentet deraf omfatter en citrullinrest ved en position, der er udvalgt fra gruppen bestående af position 4, position 12, position 19, position 42, position 61, position 86 og position 227 ifølge SEQ ID NO: 5.
2. Protein ifølge krav 1, der omfatter en aminosekvens udvalgt fra gruppen bestående af SEQ ID NO: 16-22.
3. Protein ifølge krav 1, hvor den artritiske tilstand er rheumatoid arthritis.
4. Sammensætning omfattende mindst ét citrullineret 14-3-3-eta-protein ifølge et hvilket som helst af kravene 1 til 3 bundet til en fast bærer.
5. Kit, der omfatter mindst ét citrullineret 14-3-3-eta-protein ifølge krav 1.
6. Fremgangsmåde til diagnosticering af en artritisk tilstand hos en person omfattende etablering af kontakt mellem en biologisk prøve fra personen og mindst ét citrullineret 14-3-3-protein eller et citrullineret fragment deraf under en betingelse, der er egnet til dannelsen af mindst ét immunkompleks mellem det citrullinerede 14-3-3-protein eller fragmentet deraf og autoantistoffcrmod det citrullinerede 14-3-3-protcin eller fragmentet deraf, der kan være til stede i den biologiske prøve; og detektering af tilstedeværelsen af immunkomplekser mellem det citrullinerede 14-3-3-protein eller fragmentet deraf og autoantistoffer mod det citrullinerede 14-3-3-protein eller fragmentet deraf, hvor tilstedeværelsen af immunkomplekseme indikerer en artritisk tilstand hos personen.
7. Fremgangsmåde ifølge krav 6, hvor detekteringstrinnet endvidere omfatter måling af mængden af autoantistoffer mod det citrullinerede 14-3-3-protein eller fragmentet deraf.
8. Fremgangsmåde ifølge krav 6, hvor det citrullinerede 14-3-3-protein er citrullineret 14-3-3-eta.
9. Fremgangsmåde ifølge krav 6, hvor det citrullinerede 14-3-3-protein er et fragment af citrullineret 14-3-3-eta.
10. Fremgangsmåde ifølge krav 6, hvor det citrullinerede 14-3-3-protein eller fragmentet deraf er detekterbart mærket med en markør udvalgt fra gruppen bestående af en radioaktiv markør, en luminescerende markør og en fluorescerende markør og et enzym.
11. Fremgangsmåde ifølge krav 6, hvor det citrullinerede 14-3-3-protein eller fragmentet deraf er bundet til en fast bærer.
12. Fremgangsmåde ifølge krav 6, hvor autoantistoffeme detekteres ved hjælp af et ELISA-assay.
13. Fremgangsmåde ifølge krav 6, hvor detekteringen sker ved chemiluminesens.
14. Fremgangsmåde ifølge krav 6, hvor den artritiske tilstand er rheumatoid arthritis.
15. Antistof rettet mod det citrullinerede 14-3-3-protein ifølge krav 1, hvor antistoffet selektivt binder til en citrullineret position udvalgt fra gruppen bestående af position 4, position 12, position 19, position 42, position 61, position 86 og position 227 ifølge SEQ ID NO: 5.
16. Ikke-human vært, der producerer er antistof ifølge krav 15.
17. Vært ifølge krav 16, hvor værten er en hybridomcellelinje.
18. Fremgangsmåde til diagnosticering og/eller prognosticering af en artritisk tilstand hos en person omfattende etablering af kontakt mellem en biologisk prøve fra personen og mindst ét antistof, der er i stand til selektivt at binde et citrullineret humant 14-3-3-protein eller et fragment deraf under en betingelse, der er egnet til dannelsen af mindst ét immunkompleks mellem antistoffet og de citrullinerede 14-3-3-proteiner, der kan være til stede i den biologiske prøve; og detektering af tilstedeværelsen, graden og/eller lokaliteten af mindst én citrullinrest i det citrullinerede 14-3-3-protein, hvor tilstedeværelsen, graden og/eller lokaliteten af den mindst ene citrullinrest indikerer en artritisk tilstand hos personen eller informerer om en prognose for personen.
DK12842377.9T 2011-10-21 2012-10-19 Antigener afledt af citrullineret 14-3-3 og anvendelser deraf i diagnosen af rheumatoid arthritis DK2768851T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161550046P 2011-10-21 2011-10-21
PCT/CA2012/050748 WO2013056377A1 (en) 2011-10-21 2012-10-19 Antigens derived from citrullinated 14-3-3 and uses thereof in the diagnosis of rheumatoid arthritis

Publications (1)

Publication Number Publication Date
DK2768851T3 true DK2768851T3 (da) 2017-09-18

Family

ID=48140274

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12842377.9T DK2768851T3 (da) 2011-10-21 2012-10-19 Antigener afledt af citrullineret 14-3-3 og anvendelser deraf i diagnosen af rheumatoid arthritis

Country Status (17)

Country Link
US (2) US10132806B2 (da)
EP (1) EP2768851B1 (da)
JP (2) JP6844939B2 (da)
KR (1) KR20140100939A (da)
CN (1) CN104011068A (da)
AU (1) AU2012325604B2 (da)
BR (1) BR112014009536A2 (da)
CA (1) CA2852758C (da)
DK (1) DK2768851T3 (da)
ES (1) ES2638331T3 (da)
HK (1) HK1201538A1 (da)
HU (1) HUE035999T2 (da)
IL (1) IL232169B (da)
IN (1) IN2014DN03200A (da)
PL (1) PL2768851T3 (da)
PT (1) PT2768851T (da)
WO (1) WO2013056377A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2768851T3 (pl) * 2011-10-21 2018-05-30 Augurex Life Sciences Corp. Antygeny pochodzące z cytrulinowanego białka 14-3-3 oraz ich zastosowania w diagnozie reumatoidalnego zapalenia stawów
AU2015257929B2 (en) * 2014-05-05 2020-06-25 Novio Th B.V. Method for the serological diagnosis of rheumatoid arthritis.
CN104262489B (zh) * 2014-09-30 2017-01-11 陈仁奋 一种环状瓜氨酸嵌合肽抗原及其应用
KR101758354B1 (ko) 2015-03-26 2017-07-17 한국과학기술연구원 신규한 시클릭 시트룰리네이티드 펩티드, 이를 포함하는 류마티스 관절염 진단용 조성물 및 이를 이용한 진단 방법, 및 류마티스 관절염 마커 스크리닝 방법
AU2016303033A1 (en) * 2015-08-06 2018-03-01 Novimmune Sa Methods and compositions for identifying patient populations for diagnosis and treatment of TLR4-dependent disorders
SG11201806696WA (en) * 2016-02-10 2018-09-27 Cayman Chemical Co Inc Anti-citrullinated hla polypeptide antibodies and uses thereof
CN106644985B (zh) * 2016-12-29 2021-02-05 广州市雷德生物科技有限公司 标志物及其应用、试剂盒、该标志物的检测方法
KR102529594B1 (ko) * 2021-06-23 2023-05-09 재단법인 아산사회복지재단 대동맥판막 협착증 진단 및 예후 예측을 위한 바이오마커로서 항-시트룰린화 펩티드 항체의 용도
CN118240057B (zh) * 2024-05-28 2024-07-23 北京大学人民医院 一种抗原肽及其在制备类风湿关节炎诊断产品中的应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US4956281A (en) 1987-06-03 1990-09-11 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3
US4981785A (en) 1988-06-06 1991-01-01 Ventrex Laboratories, Inc. Apparatus and method for performing immunoassays
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
US6596476B1 (en) 1989-12-22 2003-07-22 Abbott Laboratories Hepatitis C assay
US5376313A (en) 1992-03-27 1994-12-27 Abbott Laboratories Injection molding a plastic assay cuvette having low birefringence
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
EP1550729B1 (en) 1992-09-25 2009-05-27 Avipep Pty Limited Target binding polypeptide comprising an IG-like VL domain linked to an IG-like VH domain
US5359681A (en) 1993-01-11 1994-10-25 University Of Washington Fiber optic sensor and methods and apparatus relating thereto
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
JP2000502450A (ja) 1995-12-22 2000-02-29 アボツト・ラボラトリーズ 蛍光偏光免疫アッセイによる診断法
US5948765A (en) 1996-03-15 1999-09-07 Washington University Inhibition of intracellular signal transduction by 14-3-3-binding peptides
US5998149A (en) 1996-04-05 1999-12-07 The United States Of America As Represented By The Department Of Health And Human Services Method of detecting transmissible spongiform encephalopathies
US5814507A (en) 1996-05-24 1998-09-29 Genentech, Inc. κ/μ-like protein tyrosine phosphatase, PTP λ
US5885529A (en) 1996-06-28 1999-03-23 Dpc Cirrus, Inc. Automated immunoassay analyzer
AU5601298A (en) 1996-12-12 1998-07-03 Neuromark Methods of detecting transmissible spongiform encephalopathies by detecting 14-3-3 protein isoforms
DE19810721A1 (de) 1998-03-12 1999-10-14 Werner Mueller Anwendung der 14-3-3 Proteine sowie Verfahren zur schnellen Bestimmung der 14-3-3 Proteine als sensitive Biomarker für Pollution u. a. mit polychlorierten Biphenylen (PCBs) und (Xeno)Östrogenen
US7011952B2 (en) 2000-02-22 2006-03-14 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
AU2001245838A1 (en) 2000-03-17 2001-10-03 Gemini Science, Inc. Soluble mast cell function associated antigen (mafa) pharmaceutical compositionsand methods of making and using them
KR100380147B1 (ko) 2001-01-18 2003-04-11 주식회사 엘지생명과학 류마티스성 자가면역 항체의 검출방법 및 검출키트
AU2002252011A1 (en) 2001-02-21 2002-09-12 Emory University 14-3-3 binding molecules as sensitizers for anticancer therapies
DE10131912A1 (de) 2001-06-06 2002-12-19 Werner E G Mueller Verwendung von 14-3-3 Proteinen und Verfahren zu deren Bestimmung
US7171311B2 (en) 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
US7172905B2 (en) 2001-08-07 2007-02-06 The University Of Chicago Polypeptide immobilization
GB0208331D0 (en) 2002-04-11 2002-05-22 Oxford Glycosciences Uk Ltd Proteins
US7101962B2 (en) 2003-05-15 2006-09-05 Bristol-Myers Squibb Company Antibodies of the P2Y10 receptor useful in altering T lymphocyte function
EP1641935A2 (en) 2003-06-25 2006-04-05 Queen's University at Kingston Methods and formulations for diagnosing, monitoring, staging and treating heart failure
WO2005053811A2 (en) 2003-11-21 2005-06-16 Johns Hopkins University Biomolecule partition motifs and uses thereof
TWI281473B (en) 2003-12-19 2007-05-21 Ind Tech Res Inst Biomarkers for liver diseases and method for using same
CA2955027A1 (en) 2004-04-15 2005-11-10 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
US20070253961A1 (en) 2004-06-09 2007-11-01 Ulsan Industrial Education Foundation Pharmaceutical Composition Comprising the Anti-4-1Bb Antibody for Treating or Preventing Rheumatoid Arthritis
GB2426581A (en) 2005-05-27 2006-11-29 Univ Nottingham Immunoassay methods
GB2428240A (en) 2005-07-14 2007-01-24 Univ Gen Ve Diagnostic method for brain damage-related disorders
WO2007095250A2 (en) * 2006-02-13 2007-08-23 The Cleveland Clinic Foundation Compositions and methods for inhibiting optic nerve damage
ES2407975T3 (es) 2006-05-09 2013-06-17 The University Of British Columbia Marcadores proteínicos de la artritis disueltos
AU2008307634A1 (en) 2007-10-03 2009-04-09 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20090093005A1 (en) 2007-10-05 2009-04-09 University Of Virginia Patent Foundation Protein-based biomarkers for abdominal aortic aneurysm
US7919262B2 (en) 2007-11-07 2011-04-05 The Uab Research Foundation 14-3-3 proteins for diagnosis of Parkinson's disease
EP3192808A1 (en) * 2007-11-27 2017-07-19 The University Of British Columbia 14-3-3 antagonists for the prevention and treatment of arthritis
US20100016173A1 (en) 2008-01-30 2010-01-21 Proteogenix, Inc. Maternal serum biomarkers for detection of pre-eclampsia
JP2012500964A (ja) 2008-05-09 2012-01-12 デューク ユニバーシティ 癌の検出と治療における自己抗体
KR101894597B1 (ko) 2009-03-11 2018-10-04 오거렉스 라이프 사이언시스 코포레이션 관절염 상태를 특성화하는 조성물 및 방법
MX355020B (es) 2010-07-09 2018-04-02 Somalogic Inc Biomarcadores de cancer de pulmon y usos de los mismos.
CN103429753A (zh) 2010-09-27 2013-12-04 私募蛋白质体公司 间皮瘤生物标记及其用途
PL2768851T3 (pl) * 2011-10-21 2018-05-30 Augurex Life Sciences Corp. Antygeny pochodzące z cytrulinowanego białka 14-3-3 oraz ich zastosowania w diagnozie reumatoidalnego zapalenia stawów

Also Published As

Publication number Publication date
IL232169A0 (en) 2014-06-30
EP2768851A1 (en) 2014-08-27
HK1201538A1 (en) 2015-09-04
ES2638331T3 (es) 2017-10-19
WO2013056377A1 (en) 2013-04-25
US10132806B2 (en) 2018-11-20
CN104011068A (zh) 2014-08-27
JP2014530826A (ja) 2014-11-20
EP2768851B1 (en) 2017-05-31
EP2768851A4 (en) 2015-03-11
US11913950B2 (en) 2024-02-27
AU2012325604A1 (en) 2014-06-05
IL232169B (en) 2018-12-31
US20190310249A1 (en) 2019-10-10
JP6844939B2 (ja) 2021-03-17
CA2852758A1 (en) 2013-04-25
BR112014009536A2 (pt) 2017-04-18
JP2019081774A (ja) 2019-05-30
IN2014DN03200A (da) 2015-05-22
CA2852758C (en) 2020-12-29
HUE035999T2 (hu) 2018-06-28
KR20140100939A (ko) 2014-08-18
PL2768851T3 (pl) 2018-05-30
PT2768851T (pt) 2017-09-08
AU2012325604B2 (en) 2017-08-03
US20140255957A1 (en) 2014-09-11

Similar Documents

Publication Publication Date Title
US11913950B2 (en) Antigens derived from citrullinated 14-3-3 and uses thereof in the diagnosis of rheumatoid arthritis
US20210333276A1 (en) Compositions and methods for characterizing arthritic conditions
EP2620770B1 (en) Novel testing method for angiitis
JP2023065484A (ja) 新規タウ種
EP2703814B1 (en) Method for detecting neurological disease associated with cognitive dysfunction by measuring epha4 extracellular domain
US20180313830A1 (en) Peptide and biomarker associated with inflammatory disorders, and uses thereof
KR101237002B1 (ko) 시트룰린화된 단백질에 특이적인 단클론 항체 및 이를 생산하는 하이브리도마 세포주
US11267854B2 (en) Complex-specific standardization of immunological methods for the quantification of S100A12
JP2021073435A (ja) 試料に含まれるペリオスチン測定の感度の改善方法